The present invention provides an epitope peptide derived from CDCA1 with the ability to induce cytotoxic T cells. The present invention also provides polynucleotides encoding the peptide, antigen-presenting cells presenting the peptide, and methods for inducing cytotoxic T cells targeting the peptide, and the antigen-presenting cells or the CTL. The present invention further includes compositions and pharmaceutical compositions using these as active ingredients. The present invention further provides treatment and / or prevention of cancer using the peptides, polynucleotides, antigen presenting cells, cytotoxic T cells of the present invention, or the pharmaceutical composition of the present invention, and / or recurrence of preoperative cancer The method of making. In addition, a method of inducing an immune response to cancer is provided.本發明提供具有細胞傷害性T細胞誘導能力之來自CDCA1的抗原決定位胜肽。本發明並提供編碼為該胜肽之多核苷酸、呈現該胜肽之抗原呈現細胞及誘導以該胜肽為標靶之細胞傷害性T細胞、及該抗原呈現細胞或該CTL之方法。本發明更包含以該等作為有效成分之組合物及藥學組合物。本發明更提供使用本發明之胜肽、多核苷酸、抗原呈現細胞、細胞傷害性T細胞、或本發明之藥學組合物來治療及/或預防癌，及/或預發術後之癌再發之方法。又，提供誘導對於癌之免疫應答之方法。
